Clinical Trial

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or in combination by participants with ccRCC.
Protocol Amendment History 2 changes
notable Enrollment increased: 125 -> 281 participants 2026-08-12
minor Trial arms changed: 3 -> 7 2026-08-12
Trial Details
NCT Number NCT07195682
Lead Sponsor Bristol-Myers Squibb
Conditions Renal Cell Carcinoma
Enrollment 281 participants
Start Date 2026-01-15
Primary Completion 2030-05-03 (estimated)
Study Completion 2031-04-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-11